AI assistant
UroGen Pharma Ltd. — Director's Dealing 2023
Feb 2, 2023
32312_dirs_2023-02-02_8f4590b5-8e1b-434e-954e-68814548711a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2023-01-31
Reporting Person: Schoenberg Mark (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-31 | Ordinary Shares | M | 500 | — | Acquired | 147127 | Direct |
| 2023-01-31 | Ordinary Shares | S | 248 | $10.12 | Disposed | 146879 | Direct |
| 2023-01-31 | Ordinary Shares | M | 2000 | — | Acquired | 148879 | Direct |
| 2023-01-31 | Ordinary Shares | S | 991 | $10.12 | Disposed | 147888 | Direct |
| 2023-01-31 | Ordinary Shares | M | 1333 | — | Acquired | 149221 | Direct |
| 2023-01-31 | Ordinary Shares | S | 661 | $10.12 | Disposed | 148560 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-01-31 | Restricted Stock Units | $ | M | 500 | Disposed | Ordinary Shares (500) | Direct | |
| 2023-01-31 | Restricted Stock Units | $ | M | 2000 | Disposed | Ordinary Shares (2000) | Direct | |
| 2023-01-31 | Restricted Stock Units | $ | M | 1333 | Disposed | Ordinary Shares (1333) | Direct | |
| 2023-01-31 | Restricted Stock Units | $ | A | 10000 | Acquired | Ordinary Shares (10000) | Direct | |
| 2023-01-31 | Employee Stock Option (right to buy) | $10.39 | A | 30000 | Acquired | 2033-01-31 | Ordinary Shares (30000) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.
F3: The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022.
F4: The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023.
F5: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026.
F6: 1/3 of the shares underlying the stock options will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026.
F7: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.